Who
Jeffrey M. Leiden
Director
Company insider
Files Form 4 as: Director, Odyssey Therapeutics; Executive Chairman, Vertex Pharmaceuticals; Director, Quest Diagnostics; Director, Millennium Pharmaceuticals; President and COO, Abbott Laboratories.
In numbers
- Trades disclosed
- 426
- Buys
- 3
- Sells
- 62
- Bought
- $300K
- Sold
- $545.0M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 31 Jan 2006
- Last trade
- 11 May 2026
- Last filed
- 11 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code C | —28,698 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,963 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —79,166 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100,000 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —96,002 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,800 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code F | $30617 at $18.00 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —79,166 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100,000 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —96,002 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code C | —28,698 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,963 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Code F | $30617 at $18.00 | filing |
| 11 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,800 | filing |
| 8 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K5,000 at $20.00 | filing |
| 8 May 2026filed 11 May 2026 | ODTX Odyssey TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K5,000 at $20.00 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —626,220 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —626,220 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.7M3,547 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.7M3,547 at $485.11 | filing |
News
Odyssey Therapeutics Announces Encouraging Phase 2a Ulcerative Colitis ResultsODTX · rttnews.com · 20 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Jeffrey M. Leiden; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.